Alaunos Therapeutics, Inc. (TCRT) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is held by 26 institutional firms.

• The collective stake of institutional investors in Alaunos Therapeutics moved to 6.2% in December 2025, a shift up from the 3.8% reported for September 2025.
• The company experienced a 66.67% quarterly change in institutional shares held, alongside a decrease of 18.75% in total owners annually.
• A review of institutional activity for Alaunos Therapeutics shows 8 of 26 filers increasing their positions, while 6 reduced their stake, and 12 remained unchanged.
• Collectively, institutional investors increased their stake in Alaunos Therapeutics to 108.54K shares as of December 2025, a change that is up by 43.42K shares quarter on quarter and up 36.41K shares year over year.
• As of December 31, 2025, VANGUARD GROUP INC held Alaunos Therapeutics's largest shareholding position with over 30.06K shares, representing 1.73% of total outstanding shares.
• Among the most significant buyers of Alaunos Therapeutics during December 2025 were TWO SIGMA INVESTMENTS, LP (18.59K), HRT FINANCIAL LP (12.60K), VANGUARD GROUP INC (9.09K), GEODE CAPITAL MANAGEMENT, LLC (3.94K), CITIGROUP INC (89).
• Leading sellers of Alaunos Therapeutics stock in December 2025 included Tower Research Capital LLC (TRC) (552), UBS Group AG (224), OSAIC HOLDINGS, INC. (89), MORGAN STANLEY (37), WELLS FARGO & COMPANY/MN (5).
• The top 10 institutional holders of Alaunos Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (30.06K), BlackRock, Inc. (21.35K), GEODE CAPITAL MANAGEMENT, LLC (19.74K), TWO SIGMA INVESTMENTS, LP (18.59K), HRT FINANCIAL LP (12.60K), MORGAN STANLEY (1.65K), UBS Group AG (1.31K), Tower Research Capital LLC (TRC) (1.08K), OSAIC HOLDINGS, INC. (1.08K), CIBC Private Wealth Group LLC (300).